Clinical Trials

Numerous clinical trials evaluate imiquimod across dermatological, infectious, and oncological indications, spanning early-phase through Phase 4 studies for conditions such as basal cell carcinoma, vulvar high-grade squamous intraepithelial lesions, mycosis fungoides, oral squamous cell carcinoma, and actinic cheilitis. Sponsored by academic institutions including Maastricht University Medical Center, Northwestern University, Erasmus Medical Center, and the Medical University of South Carolina, these investigations encompass completed, active non-recruiting, currently recruiting, terminated, and withdrawn cohorts.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05212246 NOT_YET_RECRUITING
Basal Cell Carcinoma
VA Office of Research and Development
 2026-09-21 PHASE3
NCT07679841 NOT_YET_RECRUITING
Vulvar Squamous Cell Carcinoma
Centre Leon Berard
 2026-09 PHASE1; PHASE2
NCT07251413 RECRUITING
Cutaneous Basal Cell Carcinoma
Instituto Oncológico Dr Rosell
 2025-10-22 PHASE1; PHASE2
NCT07210775 RECRUITING
Oral Dysplasia; Leukoplakia Oral; Leukoplakia
University of Southern California
 2025-10-01 PHASE1; PHASE2
NCT05838599 RECRUITING
Mycosis Fungoides
Northwestern University
 2023-07-24 EARLY_PHASE1
NCT02600949 ENROLLING_BY_INVITATION
Metastatic Colorectal Adenocarcinoma; Metastatic Pancreatic Ductal Adenocarcinoma; Stage IV Colorectal Cancer AJCC v7; Stage IV Pancreatic Cancer AJCC v6 and v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7
M.D. Anderson Cancer Center
 2016-05-11 PHASE1
NCT06356012 RECRUITING
HSIL, High-Grade Squamous Intraepithelial Lesions; Vaginal Microbiome; Biomarkers
Barretos Cancer Hospital
 2024-04-02 PHASE4
NCT04808245 ACTIVE_NOT_RECRUITING
Newly Diagnosed H3-mutated Glioma
German Cancer Research Center
 2023-02-15 PHASE1
NCT06686043 RECRUITING
Cervical Carcinoma; Vaginal Carcinoma; Vulvar Carcinoma; HPV (Human Papillomavirus)-Associated Carcinoma
Baylor College of Medicine
 2024-08-23 PHASE2
NCT03872947 ACTIVE_NOT_RECRUITING
Solid Tumor; Colorectal Cancer; Cholangiocarcinoma; Bladder Cancer; Ovarian Cancer; Gastric Cancer; Palpable Subcutaneous Malignant Lesions; Renal Cell Carcinoma; Melanoma; Epithelial Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer
Toray Industries, Inc
 2019-04-26 PHASE1
NCT06840470 COMPLETED
Sebaceous Hyperplasia
University of Michigan
 2025-03-11 PHASE4
NCT06170983 UNKNOWN
Skin Infection
Medical University of Vienna
 2024-01-01
NCT01795313 TERMINATED
Ependymoma
James Felker
 2012-08 PHASE1
NCT06411106 UNKNOWN
Cutaneous Lupus Erythematosus
Centre for Human Drug Research, Netherlands
 2024-06
NCT00799110 TERMINATED
Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer
Beth Israel Deaconess Medical Center
 2008-05 PHASE2
NCT03534947 COMPLETED
Basal Cell Carcinoma; Basal Cell Carcinoma of Skin, Site Unspecified; Skin Cancer; Invasive Carcinoma
Melanoma Institute Australia
 2019-07-23 PHASE2
NCT05028322 UNKNOWN
Cirrhosis, Liver; Vaccination Failure; HBV; Vaccine Reaction
Central Hospital, Nancy, France
 2021-11-01 PHASE2
NCT05468606 UNKNOWN
Malaria,Falciparum
Leiden University Medical Center
 2023-02-03 EARLY_PHASE1
NCT03289260 UNKNOWN
Anogenital Human Papillomavirus Infection; Condyloma Anal
Medical University Innsbruck
 2021-11-15 PHASE3
NCT06252857 Recruiting
Basal Cell Carcinoma
Maastricht University Medical Center
 2024-04-22 --
NCT05740969 UNKNOWN
Actinic Keratoses
Ismail Gögenur
 2023-02-01 PHASE2
NCT02059499 COMPLETED
Anal Intraepithelial Neoplasia; High-grade Squamous Intraepithelial Lesion; HIV Infection
AIDS Malignancy Consortium
 2015-12-28 PHASE3
NCT06052696 Not yet recruiting
Vulvar HSIL|HPV
Erasmus Medical Center|Dutch Cancer Society
 2023-12-01 Phase 4
NCT05315024 UNKNOWN
Influenza
The University of Hong Kong
 2022-04-30
NCT00788164 COMPLETED
Cervical Cancer; Precancerous Condition; HPV Disease; Human Papilomavirus
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
 2008-11 PHASE1
NCT05838599 Recruiting
Mycosis Fungoides
Northwestern University
 2023-07-24 Early Phase 1
NCT04883645 COMPLETED
Oral Squamous Cell Carcinoma
Medical University of South Carolina
 2022-04-28 EARLY_PHASE1
NCT02889159 COMPLETED
Photoaged Skin; Normal Skin
University of Michigan
 2016-06-06 PHASE1
NCT05314127 UNKNOWN
Warts Flat
Zagazig University
 2022-04-15 PHASE2
NCT04143451 UNKNOWN
Influenza
The University of Hong Kong
 2019-10-23 PHASE3
NCT02802943 COMPLETED
Leukemia, Chronic Lymphatic
University Hospital Tuebingen
 2016-10-05 PHASE2
NCT05146895 UNKNOWN
Human Papilloma Virus
First Hospital of China Medical University
 2018-10-20
NCT02864147 COMPLETED
Cervical Intraepithelial Neoplasia; Cervical Dysplasia
Yale University
 2016-07 PHASE2
NCT05315024 Unknown status
Influenza
The University of Hong Kong
 2022-04-30 Not Applicable
NCT04883645 Active not recruiting
Oral Cancer
Medical University of South Carolina
 2022-04-28 Early Phase 1
NCT02301494 WITHDRAWN
Mycosis Fungoides
Rochester General Hospital
 2020-04
NCT03559413 COMPLETED
Primary/Relapsed Acute Lymphoblastic Leukemia (ALL) of Childhood, Adolescents and Young Adults
University Children's Hospital Tuebingen
 2016-06 PHASE1; PHASE2
NCT02394132 COMPLETED
Lentigo Maligna
Melanoma and Skin Cancer Trials Limited
 2015-08-31 PHASE3
NCT01088737 UNKNOWN
Lentigo Maligna
Medical University of Graz
 2011-01 PHASE2; PHASE3
NCT04072900 UNKNOWN
Melanoma (Skin)
Xiangya Hospital of Central South University
 2020-04-21 PHASE1
NCT04842422 COMPLETED
Actinic Keratoses
Medical University of Graz
 2021-04-16 PHASE4
NCT02135419 COMPLETED
Anal Cancer; High-grade Squamous Intraepithelial Lesion; HIV Infection; Human Papilloma Virus Infection
AIDS Malignancy Consortium
 2014-09-24 PHASE3
NCT03943407 WITHDRAWN
Itch
Aalborg University
 2019-11-01
NCT03982004 TERMINATED
Metastatic Breast Cancer
Washington University School of Medicine
 2020-09-14 PHASE1
NCT01861535 COMPLETED
Vulvar Intraepithelial Neoplasia
Medical University of Graz
 2013-06 PHASE3
NCT03116659 UNKNOWN
Lymphoma, T-Cell, Cutaneous
James J. Peters Veterans Affairs Medical Center
 2018-02-01 EARLY_PHASE1
NCT04083157 COMPLETED
Inflammatory Bowel Diseases; Hepatitis B
The University of Hong Kong
 2019-08-12 PHASE2; PHASE3
NCT03196180 COMPLETED
Cervical Intraepithelial Neoplasia Grade 2/3; Cervical Squamous Cell Carcinoma In Situ; Cervical Squamous Intraepithelial Neoplasia 2; High Grade Cervical Intraepithelial Neoplasia
National Cancer Institute (NCI)
 2019-10-15 EARLY_PHASE1
NCT03180684 COMPLETED
Vulvar High Grade Squamous Intraepithelial Lesion (HSIL); Vulvar Dysplasia; Vulvar Intraepithelial Neoplasia (VIN); VIN2; VIN3; Pre-cancerous Lesions of the Vulva; Human Papillomavirus (HPV)
Inovio Pharmaceuticals
 2017-08-31 PHASE2
NCT04219358 TERMINATED
Actinic Cheilitis
Hospital de Clinicas de Porto Alegre
 2019-03-23 PHASE1
NCT04859361 UNKNOWN
Intraepithelial Neoplasia, Cervical
University Medical Centre Maribor
 2018-11-20
NCT03901690 UNKNOWN
Genital Wart Virus Infection
Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri
 2019-08-27 PHASE3
NCT03233412 COMPLETED
High Grade Intraepithelial Neoplasia; Cervix Cancer
Barretos Cancer Hospital
 2018-01-01 PHASE2
NCT03276832 COMPLETED
Metastatic Melanoma; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7
Mayo Clinic
 2017-12-20 EARLY_PHASE1
NCT01720407 COMPLETED
Lentigo Maligna Melanoma (Head or Neck)
Nantes University Hospital
 2012-12 PHASE3
NCT01803152 COMPLETED
Sarcoma; Soft Tissue Sarcoma; Bone Sarcoma
Macarena De La Fuente, MD
 2014-01-06 PHASE1
NCT03760250 TERMINATED
Keloid
University of Pennsylvania
 2019-02-05 PHASE2
NCT01926496 COMPLETED
Actinic Keratosis (AK)
LEO Pharma
 2013-09-11 PHASE4
NCT03307902 COMPLETED
Hepatitis B
The University of Hong Kong
 2016-10-01 PHASE2; PHASE3
NCT03472976 COMPLETED
Avian Influenza; Influenza Immunisation
National Institute of Allergy and Infectious Diseases (NIAID)
 2018-06-13 PHASE1
NCT02669459 UNKNOWN
Cervical Intraepithelial Neoplasia
Erasmus Medical Center
 2016-05 PHASE3
NCT02621112 COMPLETED
Renal Failure
The University of Hong Kong
 2016-01 PHASE2; PHASE3
NCT01808820 COMPLETED
Malignant Glioma; Glioblastoma Multiforme; Anaplastic Astrocytoma; High Grade Glioma
Macarena De La Fuente, MD
 2013-08-21 PHASE1
NCT03206138 UNKNOWN
Cervical Intraepithelial Neoplasia 3
Seoul St. Mary's Hospital
 2017-05-30
NCT02224599 TERMINATED
Progressive Solid Malignancies; Refractory Solid Malignancies; Cancer
Kiromic BioPharma Inc.
 2017-07-28 PHASE1; PHASE2
NCT02234921 COMPLETED
Adenocarcinoma of the Prostate
UbiVac
 2014-10-24 PHASE1
NCT02281682 UNKNOWN
Keratosis, Actinic
Maastricht University Medical Center
 2014-11 PHASE4
NCT02917746 UNKNOWN
Cervical Intraepithelial Neoplasia
Maastricht University Medical Center
 2016-11
NCT02385188 COMPLETED
Paget Disease, Extramammary
University Medical Center Nijmegen
 2015-05 PHASE3
NCT00504023 COMPLETED
Vulvar Cancer
Memorial Sloan Kettering Cancer Center
 2007-04
NCT02242929 UNKNOWN
Nodular Basal Cell Carcinoma
Maastricht University Medical Center
 2016-01 PHASE3
NCT01678352 COMPLETED
High Risk WHO Grade II Glioma; Recurrent/Post-Chemotherapy WHO Grade II Glioma
Frank Lieberman
 2012-10 EARLY_PHASE1
NCT02452307 UNKNOWN
Recurrent Prostate Cancer
University Hospital Tuebingen
 2004-04 PHASE1; PHASE2
NCT02078648 COMPLETED
Adult Brain Glioblastoma; Glioblastoma Multiforme
Stemline Therapeutics, Inc.
 2014-05 PHASE1; PHASE2
NCT01283763 TERMINATED
Cervical Intraepithelial Neoplasia
Medical University of Vienna
 2013-05 PHASE3
NCT02276300 COMPLETED
Gastric Cancer; Breast Cancer
Technical University of Munich
 2014-12 PHASE1
NCT02960815 COMPLETED
Influenza Vaccine
University of Lausanne Hospitals
 2016-11 PHASE2
NCT03071679 COMPLETED
Healthy
Maruho Co., Ltd.
 2017-02-06 PHASE1
NCT02130323 COMPLETED
Cervical Intraepithelial Neoplasia
United States Naval Medical Center, San Diego
 2015-02 PHASE2; PHASE3
NCT01909752 COMPLETED
Carcinoma, Non-Small-Cell Lung
UbiVac
 2013-07 PHASE2
NCT01902771 TERMINATED
Glioma; Brain Cancer; Brain Tumor; Glioblastoma Multiforme; High Grade Glioma
Edward Ziga
 2013-09-03 PHASE1
NCT01543464 TERMINATED
Malignant Melanoma
Inge Marie Svane
 2012-05 PHASE2
NCT02689726 TERMINATED
HPV 16- and/or HPV 18-Infected Women With Normal Cytology, ASCUS, or LSIL
Genticel
 2015-08 PHASE1
NCT01421017 COMPLETED
Breast Cancer; Metastatic Breast Cancer; Recurrent Breast Cancer
NYU Langone Health
 2011-08-19 PHASE1; PHASE2
NCT00988559 COMPLETED
HPV16 Positive; Cervical Intraepithelial Neoplasia (CIN 2/3)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
 2009-09 PHASE1
NCT02329171 TERMINATED
Cervical Intraepithelial Neoplasia
Maastricht University Medical Center
 2014-12 PHASE3
NCT01400672 TERMINATED
Diffuse Intrinsic Pontine Glioma
Masonic Cancer Center, University of Minnesota
 2012-07-17 PHASE1
NCT01663558 WITHDRAWN
Anal Dysplasia; Human Papilloma Virus; HIV
United States Naval Medical Center, San Diego
 2015-05 PHASE4
NCT03914417 COMPLETED
Actinic Keratosis
Icahn School of Medicine at Mount Sinai
 2013-01 PHASE2
NCT01453179 COMPLETED
Actinic Keratosis
MEDA Pharma GmbH & Co. KG
 2011-10 PHASE4
NCT01059110 TERMINATED
Plantar Warts
Assistance Publique - Hôpitaux de Paris
 2010-02 PHASE4
NCT01792505 COMPLETED
Malignant Glioma
Cedars-Sinai Medical Center
 2009-10 PHASE1
NCT02103023 COMPLETED
Influenza Viral Infections
The University of Hong Kong
 2014-03 PHASE3
NCT01538901 TERMINATED
Actinic Keratoses
Medical University of Vienna
 2012-09 PHASE4
NCT00638651 COMPLETED
Healthy
University of Miami
 2008-02 PHASE1
NCT02052687 COMPLETED
Healthy
Novartis Pharmaceuticals
 2014-01 PHASE1
NCT02120898 COMPLETED
Actinic Keratosis
Actavis Inc.
 2013-10-10 PHASE3
NCT01403285 TERMINATED
Glioblastoma
Immatics Biotechnologies GmbH
 2011-08 PHASE1
NCT01788007 COMPLETED
Actinic Keratosis
Sun Pharmaceutical Industries, Inc.
 2013-01 PHASE1
NCT01686152 COMPLETED
Actinic Keratosis
Teva Pharmaceuticals USA
 2012-09 PHASE3
NCT00979550 TERMINATED
Port Wine Stains
Henry Vasconez
 2008-10 PHASE2
NCT01413763 UNKNOWN
Actinic Keratosis
Medicis Global Service Corporation
 2011-07 PHASE4
NCT01593124 COMPLETED
Vaginal Inflammation; Vaginal Infections
CONRAD
 2012-05 PHASE2
NCT00707174 COMPLETED
Cancer; Lentigo Maligna
University of Utah
 2005-03
NCT00849992 COMPLETED
Actinic Cheilitis
Norwegian University of Science and Technology
 2009-03 PHASE4
NCT01611480 COMPLETED
Actinic Keratosis
Moberg Pharma AB
 PHASE2
NCT01508884 COMPLETED
Chronic Illness
The University of Hong Kong
 2012-01
NCT00821964 COMPLETED
Male Breast Cancer; Recurrent Breast Cancer; Skin Metastases; Stage IV Breast Cancer
University of Washington
 2008-12 PHASE2
NCT00777127 COMPLETED
Actinic Keratosis
MEDA Pharma GmbH & Co. KG
 2008-12 PHASE4
NCT00803907 UNKNOWN
Carcinoma, Basal Cell
University of Sao Paulo
 2008-12 PHASE4
NCT01191034 TERMINATED
Metastatic Melanoma
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
 2010-08 PHASE1; PHASE2
NCT00585247 COMPLETED
Port Wine Stain
University of California, Irvine
 2006-11
NCT01264731 COMPLETED
Melanoma
University of Virginia
 2011-01 PHASE1
NCT01171469 COMPLETED
Brain Tumor; Glioblastoma; Medulloblastoma; Ependymoma; Anaplastic Astrocytoma
Masonic Cancer Center, University of Minnesota
 2010-09 PHASE1
NCT01161888 COMPLETED
Lentigo Maligna
Jerry Marsden
 2010-06 PHASE4
NCT00596336 TERMINATED
Chronic Lymphocytic Leukemia
The Royal Bournemouth Hospital
 2007-10 PHASE2
NCT01203878 TERMINATED
Actinic Keratosis
Tennessee Clinical Research Center
 2010-09 PHASE4
NCT00581425 COMPLETED
Basal Cell Carcinoma
The University of Texas Health Science Center, Houston
 2007-12 PHASE4
NCT01502020 COMPLETED
Actinic Keratoses
Actavis Mid-Atlantic LLC
 2011-02
NCT01229319 UNKNOWN
Actinic Keratosis
Frankel, Amylynne, M.D.
 2010-10 PHASE4
NCT00899574 COMPLETED
Breast Cancer; Breast Neoplasms
NYU Langone Health
 2009-05 PHASE2
NCT00941252 COMPLETED
Cervical Intraepithelial Neoplasia
Medical University of Vienna
 2009-07 PHASE2; PHASE3
NCT01935310 COMPLETED
Photoaging
CES University
 2010-07
NCT00470392 TERMINATED
Psoriasis
VA Office of Research and Development
 2007-05
NCT00273910 COMPLETED
High-Risk Melanoma
National Cancer Institute (NCI)
 2006-01 PHASE2
NCT00865644 COMPLETED
Neurofibromatosis Type 1; Cutaneous Neurofibromas
Massachusetts General Hospital
 2009-03 PHASE1
NCT01380314 COMPLETED
Cutaneous Leishmaniasis
Foundation Fader
 2008-03 PHASE2
NCT00774787 COMPLETED
Actinic Keratoses
Rigel Dermatology
 2008-10 PHASE4
NCT00894647 COMPLETED
Actinic Keratosis
Graceway Pharmaceuticals, LLC
 2009-05 PHASE3
NCT01212549 COMPLETED
Basal Cell Carcinoma
University of Ioannina
 2009-02 PHASE3
NCT00941811 COMPLETED
HPV
Medical University of Vienna
 2008-12 PHASE2
NCT00651703 COMPLETED
Malignant Melanoma
Cytos Biotechnology AG
 2008-04 PHASE2
NCT00814528 WITHDRAWN
Actinic Keratosis
University of Chicago
 2007-11
NCT00147771 COMPLETED
Scleroderma, Localized
The Hospital for Sick Children
 2005-09 PHASE3
NCT00674739 COMPLETED
Genital Warts
Graceway Pharmaceuticals, LLC
 2008-05 PHASE3
NCT00735462 COMPLETED
Genital Warts
Graceway Pharmaceuticals, LLC
 2008-08 PHASE3
NCT00948428 COMPLETED
Actinic Keratoses
Actavis Inc.
 2008-05 PHASE3
NCT00453050 COMPLETED
Melanoma (Skin); Metastatic Cancer
University of Oklahoma
 2006-03 PHASE1
NCT00828568 COMPLETED
Actinic Keratosis
Sun Pharmaceutical Industries, Inc.
 2008-06 PHASE1
NCT00384124 UNKNOWN
Bowens Disease
Brooke Army Medical Center
 2006-11 PHASE2; PHASE3
NCT00859105 COMPLETED
Actinic Keratosis
Apotex Inc.
 2008-02 PHASE3
NCT00605176 COMPLETED
Actinic Keratoses
Graceway Pharmaceuticals, LLC
 2008-01 PHASE3
NCT00603798 COMPLETED
Actinic Keratosis
Graceway Pharmaceuticals, LLC
 2008-01 PHASE3
NCT00189293 COMPLETED
Genital Warts
MEDA Pharma GmbH & Co. KG
 2005-06 PHASE4
NCT00189280 COMPLETED
Carcinoma, Basal Cell
MEDA Pharma GmbH & Co. KG
 2003-05 PHASE3
NCT00116649 COMPLETED
Keratosis
Graceway Pharmaceuticals, LLC
 2005-06 PHASE4
NCT00189306 COMPLETED
Superficial Basal Cell Carcinoma
Graceway Pharmaceuticals, LLC
 2001-03 PHASE3
NCT00189241 COMPLETED
Basal Cell Carcinoma
MEDA Pharma GmbH & Co. KG
 2001-02 PHASE3
NCT00294320 COMPLETED
Actinic Keratosis
MEDA Pharma GmbH & Co. KG
 2006-02 PHASE3
NCT00110682 COMPLETED
Keratosis; Actinic Keratosis
Derm Research @ 888 Inc.
 2005-04 PHASE4
NCT00601016 COMPLETED
Hemangioma, Capillary
St. Justine's Hospital
 2005-03 PHASE2
NCT00118313 COMPLETED
Melanoma (Skin)
Craig L Slingluff, Jr
 2004-11-04 PHASE1
NCT00257530 COMPLETED
Cutaneous Leishmaniasis
Drugs for Neglected Diseases
 2005-12 PHASE3
NCT00142454 COMPLETED
Malignant Melanoma
Ludwig Institute for Cancer Research
 2005-08-24 PHASE1
NCT00129519 COMPLETED
Basal Cell Carcinoma
Graceway Pharmaceuticals, LLC
 2004-01 PHASE3
NCT00031759 COMPLETED
Cervical Cancer; Precancerous Condition
Alliance for Clinical Trials in Oncology
 1999-06 PHASE2
NCT00761371 COMPLETED
Warts
MEDA Pharma GmbH & Co. KG
 2002-08 PHASE4
NCT00335179 COMPLETED
Actinic Keratosis
Graceway Pharmaceuticals, LLC
 2003-01 PHASE2
NCT00230373 WITHDRAWN
Morphea
University of Alberta
 2005-11 PHASE3
NCT01567683 COMPLETED
Healthy
Moberg Pharma AB
 PHASE1
NCT00189267 COMPLETED
Actinic Keratosis
MEDA Pharma GmbH & Co. KG
 2002-11 PHASE2
NCT00463359 UNKNOWN
Basal Cell Carcinoma
University of Glasgow
NCT00204555 COMPLETED
Carcinoma, Basal Cell
University Hospital Tuebingen
 2002-01 PHASE4
NCT00079300 COMPLETED
Non-melanomatous Skin Cancer
National Naval Medical Center
 2004-01 PHASE1
NCT00115154 COMPLETED
Keratosis
Graceway Pharmaceuticals, LLC
 2005-05 PHASE4
NCT00066872 COMPLETED
Non-melanomatous Skin Cancer
Queen's Medical Center
 2002-10 PHASE3
NCT00175643 COMPLETED
Actinic Keratoses
University of British Columbia
 2005-02 PHASE3
NCT00314756 COMPLETED
Basal Cell Carcinoma
Wake Forest University
 2005-03 PHASE4

(data from https://clinicaltrials.gov, updated on 2026-08-21)

Check the Imiquimod product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Imiquimod functions as a synthetic immune response modifier by selectively binding Toll-like receptor 7, which activates NF-κB signaling pathways to induce pro-inflammatory cytokines such as interferon-alpha while downregulating anti-apoptotic Bcl-2 expression. This local immune activation and induction of cell death provide the mechanistic basis for its therapeutic evaluation in clinical trials for conditions such as basal cell carcinoma and oral squamous cell carcinoma.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.